Literature DB >> 22337394

Lymphatic malformation: risk of progression during childhood and adolescence.

Aladdin H Hassanein1, John B Mulliken, Steven J Fishman, Nicola A Quatrano, David Zurakowski, Arin K Greene.   

Abstract

Lymphatic malformations (LMs) in soft tissues tend to enlarge over time, causing distortion, obstruction, and functional problems. The purpose of this study was to determine the natural progression of LMs to facilitate patient counseling, gain insight into pathophysiology, and guide therapy. Our Vascular Anomalies Center database was reviewed for patients with cutaneous and soft tissue LMs; combined or visceral lesions were excluded. Predictive variables were age, channel type (macrocystic, microcystic, combined), sex, lesion size (localized, diffuse), and location (head/neck, extremities, trunk). The outcome variable was natural progression of the malformation defined by expansion or the onset/worsening of signs and symptoms. The study included 441 patients: 234 females (53.1%) and 207 males (46.9%). Lymphatic malformations were located in the head/neck (61.2%), extremities (17.5%), trunk (16.1%), or multiple sites (5.2%). Children had a 42.2% risk of progression before adolescence, 84.7% before adulthood, and 95.3% during their lifetime. Progression was more likely in adolescence (63.8%) than in childhood (40.8%); the odds ratio was 2.6 (P=0.003). Diffuse LMs worsened more often than localized lesions (P=0.001), whereas channel type (P=0.63), sex (P=0.42), and location (P=0.28) did not influence progression.Lymphatic malformations have a greater risk of progression in adolescence than in childhood; pubertal hormones may contribute to expansion. Because of this high rate of progression, early treatment of asymptomatic LMs should be considered.

Entities:  

Mesh:

Year:  2012        PMID: 22337394     DOI: 10.1097/SCS.0b013e3182413ea8

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  9 in total

1.  Is there a risk of pubertal worsening in primary intestinal lymphangiectasia?

Authors:  V Salpietro; M Ruggieri; T Alterio; R Mallamace; V Chirico; T Arrigo; C Romano
Journal:  J Endocrinol Invest       Date:  2013-05-22       Impact factor: 4.256

2.  Tumor or Inflammatory Myofibroblastic Reaction in an Adolescent With an Abdominal Lymphatic Malformation?

Authors:  Joseph J Lee; Romeo C Ignacio; Diego A Vicente; Angela M Bachmann; Pamela M Choi
Journal:  Cureus       Date:  2022-03-31

3.  An open-label study to evaluate sildenafil for the treatment of lymphatic malformations.

Authors:  Christina Danial; Andrea L Tichy; Umar Tariq; Glenda L Swetman; Phuong Khuu; Thomas H Leung; Latanya Benjamin; Joyce Teng; Shreyas S Vasanawala; Alfred T Lane
Journal:  J Am Acad Dermatol       Date:  2014-03-20       Impact factor: 11.527

4.  Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.

Authors:  Li-Chin Yao; Chiara Testini; Denis Tvorogov; Andrey Anisimov; Sara O Vargas; Peter Baluk; Bronislaw Pytowski; Lena Claesson-Welsh; Kari Alitalo; Donald M McDonald
Journal:  Circ Res       Date:  2014-01-15       Impact factor: 17.367

5.  Craniofacial CT findings of Gorham-Stout disease and generalized lymphatic anomaly.

Authors:  Hiroki Kato; Michio Ozeki; Toshiyuki Fukao; Masayuki Matsuo
Journal:  Neuroradiology       Date:  2016-04-28       Impact factor: 2.804

6.  Clinical and ultrasound characteristics of pediatric lateral neck masses.

Authors:  Nemanja Rankovic; Jovana Todorovic; Radoje Simic
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

7.  Quality of Life in Swiss Patients With Spongiform Venous Malformations.

Authors:  Bojan Spahic; Daniel G Hasselmann; Michael Kostrzewa; Thomas O Meier; Stephan Engelberger; Robert K Clemens
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

8.  Venolymphatic malformation in lateral edge of the tongue: case report.

Authors:  Erasmo Freitas de Souza; Dáurea Adília Cóbe Sena; Virgínia Raquel Dos Santos Lucena; Lélia Batista de Souza; Hécio Henrique Araújo de Morais
Journal:  J Vasc Bras       Date:  2022-03-07

Review 9.  Personalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and Taxol.

Authors:  Jochen Rössler; Ulrich Saueressig; Gian Kayser; Moritz von Winterfeld; Gianoula L Klement
Journal:  J Pediatr Hematol Oncol       Date:  2015-11       Impact factor: 1.289

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.